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Nitric Oxide Regulates
Exocytosis by S-Nitrosylation
of N-ethylmaleimide-Sensitive Factor
transplant vasculopathy is exacerbated in mice lacking
NOS2, and the response to vascular injury is accelerated
in NOS3 null mice (Kuhlencordt et al., 2001a, 2001b;
Rudic et al., 1998). However, the molecular basis for
the anti-inflammatory properties of NO is not completely
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where it regulates leukocyte rolling and extravasation
(Mayadas et al., 1993; McEver et al., 1989). SecretagoguesSummary
such as thrombin, histamine, fibrin, complement, leuko-
trienes, and ATP all trigger Weibel-Palade body exo-Nitric oxide (NO) inhibits vascular inflammation, but
cytosis within minutes. Although the molecular machin-the molecular basis for its anti-inflammatory proper-
ery regulating Weibel-Palade body exocytosis is notties is unknown. We show that NO inhibits exocytosis
defined, it is likely that proteins that regulate vesicleof Weibel-Palade bodies, endothelial granules that
trafficking in other cells also regulate Weibel-Palademediate vascular inflammation and thrombosis, by
body exocytosis in endothelial cells.regulating the activity of N-ethylmaleimide-sensitive
Vesicle trafficking involves targeting of a vesicle to afactor (NSF). NO inhibits NSF disassembly of soluble
specific membrane, priming of the vesicle, and mem-NSF attachment protein receptor (SNARE) complexes
brane fusion, followed by recycling of trafficking compo-by nitrosylating critical cysteine residues of NSF. NO
nents (Jahn et al., 2003; Jahn and Sudhof, 1999; Mellmanmay regulate exocytosis in a variety of physiological
and Warren, 2000; Rothman and Wieland, 1996; Springerprocesses, including vascular inflammation, neuro-
et al., 1999; Wickner and Haas, 2000). At least fourtransmission, thrombosis, and cytotoxic T lymphocyte
classes of proteins regulate membrane fusion: Rab andcell killing.
Rab effectors, which regulate vesicle tethering to target
membranes; soluble NSF receptor (SNARE) proteins,Introduction
which are localized to vesicle and target membranes
and assemble into stable ternary complexes; members
Nitric oxide (NO) is a messenger molecule produced by of the Sec1/Munc18 protein family; and NSF, along with
the NO synthase (NOS) isoforms neuronal NOS (nNOS, the family of soluble NSF attachment proteins (SNAP),
or NOS1), inducible NOS (iNOS, or NOS2), and endothe- which plays a critical role in regulating vesicle trafficking
lial NOS (eNOS, or NOS3) (Nathan and Xie, 1994; Stamler by hydrolyzing ATP and disassembling SNARE com-
et al., 1992). All three NOS isoforms can be found in the plexes.
vasculature—NOS1 in nerve fibers in the adventitia, NSF was first identified as a cytosolic protein neces-
NOS2 in vascular smooth muscle cells and in infiltrating sary for in vitro reconstitution of intercisternal Golgi
macrophages during vascular inflammation, and NOS3 transport, and subsequently was shown to regulate in-
in endothelial cells—and NO has a variety of effects tracellular transport in yeast, nematodes, insects, and
upon vascular cells (Christopherson and Bredt, 1997; mammals (Block et al., 1988; Kaiser and Schekman,
Michel and Feron, 1997; Papapetropoulos et al., 1999; 1990; Malhotra et al., 1988; May et al., 2001). NSF forms
Radomski and Moncada, 1993). NO relaxes smooth homohexamers, hydrolyzes ATP, and alters the confor-
muscle, inhibits smooth muscle cell migration and prolif- mation of the stable SNARE complex (Block et al., 1988;
eration, and decreases platelet adherence and aggrega- Malhotra et al., 1988). NSF is composed of three do-
tion. NO also inhibits vascular inflammation: atheroscle- mains: an N-terminal domain and two homologous ATP
rosis is increased in mice deficient in NOS2 or NOS3, binding domains. The N-terminal domain (residues 1–205)
interacts with members of the SNAP family, which in turn
interact with SNARE molecules. The D1 domain (resi-*Correspondence: clowenst@jhmi.edu
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dues 206–488) hydrolyzes ATP and provides the me-
chanical force to disassemble SNARE complexes. The
D2 domain (residues 489–744) mediates NSF hexameri-
zation.
Although NSF regulates vesicle trafficking and exo-
cytosis, the regulation of NSF is not well understood.
Sensitivity to NEM suggests that NSF might be regulated
by S-nitrosylation, a mechanism by which NO modulates
protein functions (Stamler, 1994; Stamler et al., 2001,
1992). We hypothesized that NO regulates exocytosis
by nitrosylating NSF. We show that NO inhibits Weibel-
Palade body exocytosis from endothelial cells, in part
by inhibiting NSF disassembly activity.
Results
Exogenous and Endogenous NO Inhibits Weibel-
Palade Body Exocytosis
To explore the effect of NO upon granule exocytosis, we
studied thrombin-induced exocytosis of Weibel-Palade
bodies from human aortic endothelial cells (HAEC),
which release von Willebrand’s Factor (vWF). We pre-
treated HAEC with 10 mM NO donor 2-(N,N-diethyl-
amino)-diazenolate-2-oxide (DEA-NONOate) or with DEA
as a control, stimulated the cells with thrombin 1 U/ml
for 1 hr, and then measured the amount of vWF released
into the media. Thrombin induces a rapid release of vWF
from HAEC (Figure 1A). However, exogenous NO blocks
the effects of thrombin (Figure 1A). Endogenous NO
produced from endothelial cells also inhibits vWF re-
lease, since 1 mM L-nitroarginine-methyl-ester (L-NAME)
inhibition of NOS for 16 hr increases the amount of vWF
released after thrombin stimulation (Figure 1A). NO inhi-
bition of vWF release is dose dependent. We pretreated
HAEC with increasing amounts of various NO donors,
including a rapidly releasing NO donor DEA-NONOate
for 10 min, a slowly releasing NO donor DETA-NONOate
for 16 hr, or a nitrosothiol S-nitroso-penicillamine (SNAP)
for 6 hr; or we treated cells with NEM for 1 hr. Pretreat-
ment with any one of these reagents inhibits thrombin
induced vWF release (Figure 1B).
Figure 1. NO Inhibits vWF Release from Human Aortic Endothelial
We then explored the role of endogenous NO in the Cells
regulation of Weibel-Palade body exocytosis. We pre- (A) Time course. HAEC were pretreated with DEA as a control or
treated HAEC with L-NAME for 16 hr in order to inhibit the NO donor DEA-NONOate or the NOS inhibitor L-NAME, and then
endogenous NOS and then stimulated the cells with incubated with thrombin for 1 hr. The amount of vWF released from
cells into the media was measured by an ELISA (n  3–5  SD).1 U/ml thrombin for 1 hr and measured vWF release.
Exogenous NO inhibits exocytosis, and L-NAME inhibition of endog-L-NAME increases thrombin-stimulated vWF release in
enous NOS increases exocytosis.a dose-dependent manner (Figure 1C). (The iNOS inhibi-
(B) Dose response. HAEC were pretreated with DEA-NONOate fortor 1400W had no effect [data not shown]). We next
10 min, DETA-NONOate for 16 hr, SNAP for 6 hr, or NEM for 1 hr
pretreated HAEC with vascular endothelial growth factor and then incubated with thrombin for 1 hr. The amount of vWF
(VEGF) in order to activate endogenous NOS3. Cells released from cells was measured by an ELISA (n  3–5  SD).
were incubated with 50 ng/ml VEGF or control for 2 (C) Inhibition of endogenous NOS increases vWF release. HAEC
were pretreated with L-NAME for 16 hr, incubated with thrombin forhr, and then stimulated with thrombin. VEGF treatment
1 hr, and vWF released from cells was measured as above (n  2 decreases thrombin stimulated vWF release (Figure 1D).
SD, *p  0.06 versus thrombin; **p  0.03 versus thrombin).L-NAME 1 mM blocks the effects of VEGF treatment,
(D) Activation of endogenous NOS decreases vWF release. HAECimplying that NO mediates VEGF inhibition of exocytosis
were pretreated with media or 1 mM L-NAME for 16 hr, stimulated
(Figure 1D). Since L-NAME inhibition of NOS increases with 50 ng/ml VEGF for 2 hr, and then incubated with thrombin. The
exocytosis and since VEGF activation of NOS decreases amount of released vWF was measured as above (n  3  SD, *p 
exocytosis, taken together, these data suggest that en- 0.01 versus control).
dogenous NO regulates endothelial cell exocytosis.
SNARE Molecules Regulate Weibel-Palade
molecules regulate exocytosis of vesicles and granulesBody Exocytosis
from other cells, we reasoned that they might also regu-The molecular machinery that regulates Weibel-Palade
body exocytosis is unknown. However, since SNARE late endothelial cell exocytosis of Weibel-Palade bodies
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Figure 2. NSF and SNARE Molecules Regu-
late Weibel-Palade Body Secretion
(A) NSF and SNARE molecules are expressed
in endothelial cells. Immunoblotting of 200g
extracts of endothelial cells or human brain
with antibodies to NSF and SNARE mole-
cules.
(B) Antibodies to SNARE molecules inhibit
Weibel-Palade body exocytosis. HAEC were
permeabilized and incubated with antibodies
to SNARE molecules. Cells were then re-
sealed, treated with thrombin, and the
amount of vWF released into the media was
measured by ELISA (n  2).
(C) Antibody to NSF inhibits Weibel-Palade
body exocytosis. HAEC were permeabilized
and incubated with antibody to NSF or
-SNAP. Cells were then resealed, treated
with thrombin, and the amount of vWF re-
leased was measured as above (n  2).
(D) NSF peptides enter HAEC. Cells were in-
cubated with FITC-labeled TAT-NSF peptide
for 20 min, treated with ethidium bromide to
quench extracellular FITC, and imaged by
FACS (n  3  SD).
(E) NSF peptides inhibit vWF release. Cells
were incubated with TAT-NSF peptides for
20 min, treated with media (left) or thrombin
(middle and right), and the amount of released
vWF was measured (n  3  SD).
as well. We first determined the expression of SNARE 25% (Figure 2C). Antibody to -SNAP also inhibits
vWF release.molecules in endothelial cells, using brain extracts as a
control. HAEC and human brain extracts were immu- Our second approach to demonstrating NSF regula-
tion of Weibel-Palade body exocytosis involved peptidenoblotted with antibodies to SNARE molecules. HAEC
express VAMP-3, syntaxin-2 and syntaxin-4, and SNAP- inhibition of NSF. We designed a peptide inhibitor of NSF
that crosses cell membranes. This peptide, designated23 (Figure 2A). To explore the role of syntaxin-4 and
VAMP-3 in the regulation of vWF release, we permeabil- TAT-NSF222, consists of the protein transduction do-
main of HIV TAT (residues 47–57) previously shown toized HAEC and then incubated them with antibody to
syntaxin-4, antibody to VAMP, or IgG as a control. Cells transduce polypeptides into cells (Becker-Hapak et al.,
2001) fused to a fragment of NSF (residues 222–243)were then resealed, treated with thrombin, and the
amount of vWF released into the media was measured. previously shown to inhibit NSF (Schweizer et al., 1998).
To show that this peptide enters HAEC, we incubatedAntibody to syntaxin-4 inhibits vWF release by over 75%
(Figure 2B). Antibody that reacts with VAMP isoforms HAEC with 10M FITC-labeled TAT-NSF or 10M FITC-
albumin for 20 min, added ethidium bromide to quench1, 2, and 3 inhibits vWF release by approximately 25%.
These results suggest that SNARE molecules regulate extracellular fluorescence, and analyzed fluorescence
of the cells by FACS. Over 75% of cells treated withWeibel-Palade body exocytosis.
FITC-TAT-NSF222 contained FITC (Figure 2D). We then
incubated HAEC for 20 min with TAT-NSF222 or with a
NSF Regulates Weibel-Palade Body Exocytosis control peptide TAT-NSF222scr that consisted of the
We next explored the role of NSF in regulating Weibel- intact TAT domain followed by the amino acid residues
Palade body exocytosis. We first determined that HAEC of NSF 222-243 in a scrambled order. HAEC were trans-
express NSF (Figure 2A). We then used two approaches duced with TAT-NSF peptides, treated with media or
to show that NSF regulates Weibel-Palade body exo- thrombin, and the amount of vWF released into the me-
cytosis. Our first approach involved antibody inhibition dia was measured by ELISA. TAT-NSF222 inhibits vWF
of exocytosis. We permeabilized HAEC as above, incu- release in a dose-dependent manner (Figure 2E).
bated cells with antibody to NSF or antibody to -SNAP, Taken together, the antibody and peptide inhibition
resealed the cells, and stimulated them with thrombin. data suggest that NSF regulates Weibel-Palade body
exocytosis.Antibody to NSF inhibits vWF release by approximately
Cell
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Figure 3. NO Inhibition of NSF
(A) NO does not inhibit NSF ATPase activity.
A colorimetric assay was used to measure
the ATPase activity of recombinant NSF that
had been treated with DEA-NONOate (n 
3  SD).
(B) NO inhibits NSF disassembly of 20S com-
plex. Recombinant NSF was pretreated or not
with 1 mM DEA-NONOate for 10 min, mixed
with -SNAP, and added to detergent ex-
tracts of HAEC membranes. ATP or ATP-S
0.5 mM was added, and the mixture was frac-
tionated by ultracentrifugation. Fractions
were collected from the bottom of the tubes
and immunoblotted with antibody to syn-
taxin-4.
(C) NO inhibits NSF disassembly activity. Re-
combinant (His)6-NSF was pretreated or not
with 1 mM DEA-NONOate and then incubated
with -SNAP, VAMP-3, SNAP-23, and GST-
syntaxin-4. ATP or ATP-S 5 mM was added,
the mixture was precipitated with glutathi-
one-sepharose, and precipitated proteins
were immunoblotted with antibodies as indi-
cated.
(D) NO inhibits NSF disassembly activity:
dose response. Recombinant NSF was pre-
treated with DEA-NONOate for 10 min, mixed
with -SNAP, and added to endothelial cell
GST-SNARE fusion polypeptides as above.
ATP 5 mM was added, GST-SNAREs were
precipitated with glutathione-sepharose, and
the precipitant was analyzed for the copreci-
pitation of NSF.
(E) TAT-NSF peptides inhibit NSF ATPase ac-
tivity. A colorimetric assay was used to mea-
sure the ATPase activity of recombinant NSF
that had been treated with TAT-NSF peptides.
(F) TAT-NSF peptides inhibit NSF disassembly
activity. Recombinant NSF was pretreated with
TAT-NSF peptides for 20 min and mixed with
-SNAP and endothelial cell GST-SNARE fu-
sion polypeptides as above. ATP was added,
GST-SNAREs were precipitated with glutathi-
one-sepharose, and the precipitant was ana-
lyzed for the coprecipitation of NSF.
(G) Exogenous NSF restores vWF exocytosis in endothelial cells treated with NO. HAEC were pretreated with 1 mM DEA-NONOate as above,
permeabilized with SLO, incubated with recombinant NSF or nitrosylated recombinant NSF, stimulated with thrombin, and the amount of vWF
in the media was measured (n  3  SD, *p  0.01 for NO versus NO  NSF).
NO Does Not Inhibit NSF ATPase Activity detergent extracts of HAEC membranes in the presence
of 0.5 mM ATP or ATP-S. These reactions were thenWe next explored the effect of NO upon NSF activity
since NO inhibits Weibel-Palade body exocytosis and fractionated by sucrose density gradient ultracentrifu-
gation and fractions were collected from the bottom ofsince NSF regulates Weibel-Palade body exocytosis.
We first examined the effect of NO upon the ATPase the tube and immunoblotted with antibody to syntaxin-4.
The SNARE complex sediments at 7S, as expected in theactivity of NSF. DEA-NONOate was added to recombi-
nant NSF, and the ATPase activity of NSF was measured. presence of NSF and ATP (Figure 3B, top). The SNARE
complex sediments at 20S, as expected in the presenceNO does not significantly inhibit NSF hydrolysis of ATP
(Figure 3A). of NSF and ATP-S (Figure 3B, middle). However, the
SNARE complex also sediments at 20S in the presence
of ATP and NSF pretreated with DEA-NONOate (FigureNO Inhibits NSF Disassembly Activity
We next explored the effect of NO upon NSF disassem- 3B, bottom). These results suggest that NO inhibits the
ability of NSF to disassemble a 20S SNARE complexbly activity. ATP is required for NSF to disassemble the
SNARE complex; ATP-S can lock NSF onto the SNARE derived from endothelial cell extracts.
We next examined the effect of NO upon NSF disas-complex. The SNARE complex alone sediments at 7S,
and the NSF--SNAP-SNARE complex sediments at ap- sembly of purified, recombinant SNARE molecules. Re-
combinant (His)6-NSF was pretreated or not with 1 mMproximately 20S. Accordingly, we pretreated recombi-
nant NSF with the NO donor DEA-NONOate 1 mM for DEA-NONOate for 10 min and then mixed with (His)6-
-SNAP and recombinant SNARE fusion polypeptides10 min. We then mixed pretreated NSF, -SNAP, and
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identified in endothelial cells: GST-syntaxin-4, VAMP-3, (Figure 4A). To determine the importance of individual
cysteine residues in NSF functions, we made nine indi-and SNAP-23. ATP or ATP-S was added, the mixture
was precipitated with glutathione-sepharose beads, vidual NSF mutants, each lacking one of the nine cys-
teine residues, and then compared the activity of wild-and precipitated proteins were fractionated by SDS-
PAGE and immunoblotted with antibody to the NSF tag. type NSF to mutant NSF.
We first determined which cysteine residues mediateNSF with -SNAP interacts with GST-syntaxin-4 (Fig-
ure 3C). ATP decreases the interaction of NSF with GST- NSF ATPase activity. We measured the ATPase activity
of wild-type NSF and of each NSF mutant. Mutation ofsyntaxin-4; ATP also decreases the coprecipitation of
VAMP-3 and SNAP-23 along with GST-syntaxin-4, pre- cysteine residues 21, 91, 264, and 334 partially decrease
NSF ATPase activity (Figure 4B, white bars).sumably by NSF disassembly of the SNARE complex.
As expected, ATP-S blocks NSF disassembly activity. We next determined which cysteine residues mediate
NSF interactions with SNARE molecules. We repeatedHowever, NO blocks NSF disassembly of the SNARE
complex, even in the presence of ATP (Figure 3C). Fur- the pull-down assay with wild-type and mutant NSF.
NSF and -SNAP were incubated with GST-SNARE fu-thermore, DTT restores the disassembly activity of NSF
pretreated with NO, suggesting that NO inhibition of sion polypeptides in the presence of ATP or ATP-S,
and the mixture was precipitated with glutathione-seph-NSF disassembly is reversible. Finally, NO inhibits NSF
disassociation from GST-syntaxin-4 in a dose-depen- arose beads, and finally, immunoblotted with antibody
to the NSF tag. Wild-type NSF interacts with GST-dent manner (Figure 3D).
(The low level of interaction between NSF and SNAREs SNAREs in the presence of ATP-S and disassembles
GST-SNAREs in the presence of ATP (Figure 4C). Muta-in the absence of adding additional ATP to the reaction
mixture may be due to residual ATP in the storage buffer tion of cysteine residues 250 and 599 have no effect on
NSF interaction and disassembly activity. Mutation ofused to prepare recombinant NSF. Small amounts of
ATP present in the reaction buffer may permit an interac- cysteine residues 11, 21, 334, 568, and 582 block the
ability of NSF to interact with GST-SNARE molecules.tion between NSF and SNAREs, while larger amounts
enable NSF to disassemble the SNARE/-SNAP/NSF Mutation of cysteine residues 91 and 264 permit NSF
to interact with the SNARE complex, but inhibit the abil-complex.)
ity of NSF to disassemble the GST-SNARE complex.
These data suggest that one set of NSF cysteine resi-TAT-NSF Peptides Inhibit NSF ATPase Activity
dues regulate NSF interactions with SNARE complexesand NSF Disassociation from SNAREs
and another set of NSF cysteine residues regulate NSFNO and TAT-NSF peptides inhibit NSF by different
disassembly of SNARE complexes. In particular, cys-mechanisms. NO inhibits NSF disassembly activity but
teine residues 91 and 264 appear to regulate NSF disas-does not affect NSF ATPase activity, as shown above.
sembly activity.In contrast, the TAT-NSF222 peptide inhibits both NSF
ATPase activity (Figure 3E) and also NSF disassembly
activity (Figure 3F). Thus, the mechanisms by which NO NSF Cysteine Residue Targets of NO
and TAT-NSF peptides inhibit NSF are different: both We next used these NSF cysteine mutants to explore
inhibit NSF disassembly activity, but only TAT-NSF pep- which cysteine residues of NSF are targets of NO. We
tides inhibit NSF ATPase activity as well. Since NO re- added NO to wild-type and mutant NSF and measured
versibly inhibits NSF disassembly activity without affect- the ATPase activity. NO does not affect ATPase activity
ing its ATPase activity, we reasoned that NO targets of wild-type NSF and does not affect ATPase activity of
NSF cysteine residues in regions of NSF that couple the any of the NSF mutants (Figure 4B, black bars).
energy of ATP hydrolysis to the mechanical energy of We then tested the effect of NO upon the disassembly
disassembling the SNARE complex. activity of NSF mutants, using the pull-down assay. NO
blocks the ability of wild-type NSF to disassemble the
NO Inhibits Exocytosis by Inhibiting NSF SNARE complex in the presence of ATP (Figure 4C).
To confirm that NSF is a primary physiological target of Mutation of cysteine residues 250 and 599 have no effect
NO, we pretreated HAEC with 1 mM DEA-NONOate for on the ability of NO to inhibit NSF disassembly activity.
10 min to inhibit exocytosis, permeabilized the endothe- The effect of NO upon cysteine residues 11, 21, 334,
lial cells as above, and then added recombinant NSF 568, and 582 cannot be ascertained, since mutation of
100 g/ml. HAEC were then resealed, stimulated with these residues abrogates NSF interaction with SNARE
thrombin, and the amount of vWF released into the me- molecules. Mutation of cysteine residues 91 and 264
dia was measured. As before, NO inhibits exocytosis blocks the ability of NSF to disassemble the SNARE
(Figure 3G). However, exogenous recombinant NSF re- complex, and NO has no effect upon these mutants.
stores the ability of NO treated HAEC to undergo exo- We next measured the number of cysteine residues
cytosis (Figure 3G). In contrast, recombinant NSF pre- that are nitrosylated by exogenous NO. We exposed
treated with NO cannot restore the ability of NO treated recombinant NSF to increasing amounts of DEA-NONO-
HAEC to undergo exocytosis (Figure 3G). These data ate and then used the Saville reaction to measure the
suggest that NSF is indeed a primary target of NO in number of nitrosocysteine residues per molecule of
cells. NSF. NO nitrosylates NSF in a dose-dependent manner
(Figure 4D). At 1 mM DEA-NONOate, approximately 3
cysteine residues are modified by NO per each moleculeCysteine Residues Mediate NSF Activity
NSF contains 9 cysteine residues, 3 in the N-terminal of NSF. (This dose of 1 mM DEA-NONOate also inhibits
NSF disassembly activity (Figure 3D).)domain, 3 in the D1 domain, and 3 in the D2 domain
Cell
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Figure 4. Cysteine Residues Mediating NSF Activity
(A) Schematic of NSF.
(B) Cysteine residues mediating ATPase activity of NSF. Wild-type NSF and mutant NSF were expressed and purified, treated with 1 mM
DEA-NONOate or DEA, and the ATPase activity was measured as above. Mutagenesis of Cys at 21, 91, 264, and 334 partially inhibits NSF
ATPase activity. NO does not inhibit ATPase activity of wild-type or mutant NSF (n  3  SD).
(C) Cysteine residues mediating disassembly activity of NSF. Wild-type NSF and mutant NSF (with mutated Cys residues) were expressed
and purified, and disassembly activity was measured by the pull-down assay as above. Mutagenesis of Cys at 11, 21, 334, 568, and 582
inhibits NSF interaction with SNARE complex. Mutagenesis of Cys at 91 and 264 permits NSF interaction with SNARE complex but blocks
NSF disassembly of SNARE complex. Mutagenesis of Cys at 250 and 599 has no effect on NSF interaction or disassembly.
(D) Nitrosylation of NSF in vitro. DEA-NONOate was added to recombinant wild-type NSF, and the molar ratio of nitrosothiols per NSF molecule
was measured by the Saville reaction. Each molecule of NSF can contain a maximum of three nitrosothiols (n  3  SD).
(E) Identification of nitrosylated cysteine residues in NSF. DEA-NONOate was added to recombinant NSF mutants, and the molar ratio of
nitrosothiols per NSF molecule was measured by the Saville reaction. Mutation of C21 or C91 or C264 decreases the nitrosothiol content of
nitrosylated NSF (n  3–5  SD).
We next identified the cysteine residues that are tar- data suggest that NO nitrosylates cysteine residues 21,
91, and 264 of NSF.gets of NO by measuring the number of cysteines that
are nitrosylated in wild-type and mutant NSF. DEA-NONO-
ate was added to wild-type or mutant NSF that lack NO Nitrosylation of NSF Is Reversible
Since NSF plays a general role in vesicle trafficking,specific cysteine residues, and the Saville reaction was
used to measure the number of nitrosocysteine residues permanent inactivation of NSF would slow vesicular traf-
ficking in general. However, local production of NO atper molecule of NSF. Mutation of cysteine residues 11,
250, 334, and 568 have no effect upon the nitrosocys- the plasma membrane and reversible nitrosylation of
NSF could provide spatial regulation of NSF. In order toteine content (Figure 4E). However, mutation of cysteine
residues 21, 91, or 264 decreases the nitrosocysteine measure how long NO inhibition of exocytosis lasts, we
pretreated HAEC with the NO donor SNAP 100 M forcontent per NSF molecule by one (Figure 4E). These
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with NO, and 2–4 hr after treatment the level of nitrosyl-
ated NSF is similar to nontreated cells (Figure 5B, top).
(In addition to the expected signal for NSF at 82 kDa,
another band at approximately 70 kDa is observed.)
Treatment with NO donors does not change the total
amount of NSF for the first 4 hr, but total amounts of NSF
increase 4–16 hr after NO treatment (Figure 5B, bottom).
Taken together, these data show that within 2-4 hr of
exposure to NO, nitrosylation of NSF, and inhibition of
endothelial cell exocytosis is reversible.
NSF Is Nitrosylated and Regulates
Exocytosis In Vivo
In order to test whether or not NO modifies NSF in vivo,
we prepared cell lysates from HAEC treated with media
or the NOS inhibitor L-NAME. Polypeptides in this lysate
containing nitrosothiols were biotinylated, precipitated
with avidin-agarose, and immunoblotted with antibody
to NSF (Jaffrey et al., 2001). NSF is nitrosylated in en-
dothelial cells, and treatment of cells with increasing
amounts of NOS inhibitor decreases NSF nitrosylation
(Figure 6A). We next searched for nitrosylated NSF in
mice. Polypeptides were prepared from spleens of wild-
type and eNOS null mice as above. NSF is nitrosylated in
wild-type mice expressing eNOS (Figure 6B). In contrast,
NSF is not nitrosylated in eNOS-deficient mice. These
data show that NO nitrosylates NSF in vivo.
To explore the physiological relevance of NSF regula-
tion of Weibel-Palade body exocytosis, we measured
the effect of the NSF inhibitory peptide upon the bleed-
ing time in mice. Anesthetized mice were injected intra-Figure 5. NO Inhibition of Exocytosis and Nitrosylation of NSF Is Re-
versible venously with saline, TAT-NSF222, or the control pep-
tide TAT-NSF222scr; after 45 min, the distal 5 mm of(A) NO inhibition of exocytosis is temporary. HAEC were pretreated
with the NO donor SNAP 100 M for 4 hr, washed to remove the tail was amputated and the bleeding time measured (if
NO donor, and then, at various times after NO treatment, thrombin the animals bled continuously for 20 min, the experiment
was added for 1 hr, and the amount of vWF released into the media was stopped, and the bleeding time was recorded as
was measured (n  3  SD).
20 min). Treatment with saline or the control peptide(B) NO nitrosylation of NSF is reversible. HAEC were pretreated with
has no effect upon bleeding time (Figure 6C). In contrast,the NO donor SNAP 100 M for 4 hr, washed to remove the NO
treatment with TAT-NSF222 dramatically prolongs thedonor, and cells were harvested at various times after treatment.
(Top) Cell lysates were immunoprecipitated with antibody to nitro- bleeding time (Figure 6C). In fact, three of the six mice
socysteine and immunoblotted with antibody to NSF. (Bottom) Total treated with the TAT-NSF222 peptide had bleeding
cell lysates were immunoblotted with antibody to NSF (this experi- times in excess of 20 min. (The NSF inhibitory peptides
ment was repeated twice with similar results).
did not enter platelets and did not affect platelet exo-
cytosis [data not shown]. The NSF inhibitory peptides
also did not affect vascular contractility of mouse aortas4 hr, washed the cells to remove the NO donor, and
perfused in organ baths [data not shown]). These datathen at various times afterwards stimulated the HAEC
show that NSF regulates Weibel-Palade body exo-with thrombin and measured the amount of vWF re-
cytosis in vivo and suggest that NSF is a novel target forleased into the media. NO inhibits thrombin-induced
treatment of thrombotic and cardiovascular diseases.release of vWF, and a single application of NO continues
to inhibit exocytosis 1 hr after treatment (Figure 5A).
However, NO inhibition of exocytosis gradually de- NO Regulates Exocytosis In Vivo
We explored the physiological relevance of NO regula-creases after 1–2 hr; and 2–4 hr after NO treatment about
75% of Weibel-Palade body exocytosis is restored (Fig- tion of Weibel-Palade body exocytosis in two murine
models. We measured the bleeding time in wild-typeure 5A). Thus, NO inhibition of exocytosis is reversible.
In order to examine directly the reversibility of NSF and eNOS-deficient mice. Lack of eNOS decreases the
bleeding time in mice, which would be predicted if anitrosylation, we pretreated endothelial cells with an NO
donor as above and then harvested cell lysates at vari- lack of NO decreased NSF inhibition and permitted an
increase in exocytosis of vWF (Figure 6D). We also mea-ous times after NO treatment. Cell lysates were immuno-
precipitated with antibody to nitrosocysteine, fraction- sured serum levels of vWF and soluble P-selectin in
wild-type and eNOS-deficient mice. Serum levels of vWFated by SDS-PAGE, and immunoblotted with antibody
to NSF. Treatment with NO increases the level of nitro- are higher in eNOS-deficient mice compared to wild-
type mice (20  25 versus 11  14 mU/ml, althoughsylated NSF (Figure 5B, top:  versus  at 0 hr). The
level of nitrosylated NSF decreases 2 hr after treatment these differences are not significant for n  6). Serum
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Figure 6. NSF Is Nitrosylated and Inhibits Ex-
ocytosis In Vivo
(A) Nitrosylation of NSF in human endothelial
cells. HAEC were treated with media alone or
the NOS inhibitor L-NAME. Nitrosothiols were
biotinylated, precipitated with avidin-aga-
rose, and precipitants were immunoblotted
with antibody to NSF. L-NAME inhibits en-
dogenous nitrosylation of NSF in human en-
dothelial cells.
(B) Nitrosylation of NSF in mice. Spleens from
wild-type mice and mice lacking eNOS were
harvested. Nitrosothiols were biotinylated,
precipitated with avidin-agarose, and precip-
itants were immunoblotted with antibody to
NSF. NSF is nitrosylated only in mice ex-
pressing eNOS.
(C) Inhibition of NSF in mice prolongs bleed-
ing time. Anesthetized mice were injected
with PBS or the TAT-NSF222 peptide that in-
hibits NSF, and after 45 min, the distal tip of
the tail was amputated and the bleeding time
was measured. Bleeding that continued
longer than 20 min was recorded as 20 min
(n  3–6  SD, *p  0.01 for TAT-NSF versus
TAT-NSFscr at 49 mg/kg).
(D) Endogenous NO prolongs bleeding time in
mice. The distal tip of the tail was amputated
from wild-type and eNOS null mice, and the
bleeding time was measured (n  7–8  SD,
*p  0.01 for wild-type versus eNOS null).
levels of soluble P-selectin are also higher in eNOS- ures 7B and 7C). Inhibition of endogenous NOS with
L-NAME increases histamine-induced platelet interac-deficient mice compared to wild-type mice (81  21
versus 73  14 mU/ml, although these differences are tions with the venule wall to a frequency more than
double that observed in nontreated mice (Figures 7Bnot significant for n  8). Conclusions from this physio-
logical model of bleeding are limited because NO has and 7C). Furthermore, inhibition of endogenous NOS
permits an increase in platelet-venule interactions,effects upon platelets as well as endothelial cells. De-
spite the limitations of this in vivo model, increased which finally peaks at 6 min after histamine treatment,
indicating that the vWF release continues twice as longlevels of vWF and soluble P-selectin and decreased
bleeding times would be expected in eNOS–deficient as in the control mice. This increase in transient platelet
adherence to the venule would be predicted if less NOmice, if NO inhibits exocytosis in vivo.
To further examine the physiological relevance of NO synthesis led to increased exocytosis of Weibel-Palade
bodies and more release of vWF.regulation of Weibel-Palade body exocytosis, we mea-
sured the effect of endogenous NO upon platelet inter- The bleeding time and platelet rolling data taken to-
gether suggest that NO regulates hemostatically impor-actions with endothelial cells in vivo. Platelet rolling, or
transient adherence of platelets to the walls of blood tant granule secretion in vivo.
vessels, is mediated by vWF released by exocytosis
(Andre et al., 2000). We hypothesized that inhibition of Discussion
endogenous NO synthesis would permit an increase in
Weibel-Palade body exocytosis, an increase in released The major finding of this study is that NO regulates
exocytosis by nitrosylating NSF, thereby inhibiting NSFvWF, and an increase in platelet adherence to venule
walls. We first showed that exogenous NO can inhibit disassembly activity. Inhibition of NOS increases endo-
thelial release of vWF and increases platelet adherencehistamine-induced exocytosis from HAEC (Figure 7A).
We next employed intravital microscopy to explore the to the stimulated vessel wall. Although NSF was origi-
nally purified as a protein necessary for intercisternaleffects of endogenous NO upon platelet rolling in vivo.
Anesthetized mice were pretreated or not with L-NAME Golgi transport that was inhibited by NEM, our data
suggests that NEM-Sensitive Factor is actually an NO-and then transfused with calcein-AM labeled platelets.
The mesentery was externalized, superfused with hista- Sensitive Factor.
mine, and intravital microscopy was used to record in-
teractions of fluorescently labeled platelets with mesen- How Does NO Inhibit NSF?
NO regulates a wide variety of proteins by nitrosylationteric venules. Platelets were classified as adherent if
they were transiently captured by the endothelium and of critical cysteine residues (Stamler, 1994; Stamler et
al., 2001, 1992). Our data suggest that NO regulates NSFthen translocated in a stop-and-go fashion for a mini-
mum of 2 s. Histamine rapidly induces platelet adhesion by covalently modifying cysteine residues of NSF C91
and C264. How might nitrosylation of C91 or C264 inhibitto the venule wall without aggregation, starting within
30 s and peaking 3 min after histamine treatment (Fig- NSF? Since NO inhibits NSF disassembly activity but
Nitric Oxide Regulation of Exocytosis
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Figure 7. NO Inhibits Exocytosis In Vivo and Consequently Platelet Adhesion to Endothelium
(A) Exogenous NO inhibits histamine induced exocytosis in vitro. HAEC were pretreated with the NO donor SNAP 100 M for 4 hr and then
stimulated with histamine for 1 hr, and the amount of released vWF was measured as above (n  2  SD, *p  0.05 versus 0 M).
(B) Inhibition of endogenous NOS increases histamine induced platelet adherence to venules in mice. Mice were pretreated or not with 5 mg/
kg L-NAME for 30 min and then transfused with calcein-AM labeled platelets. Intravital microscopy was used to visualize fluorescent platelets
adhering to mesenteric venules 5 min after superfusion with 10 l of 1 mM histamine. The dotted line indicates the edge of the mesenteric
venule. The arrow points to a fluorescent platelet adhering to the vessel wall (bar  50 m).
(C) Inhibition of endogenous NOS increases platelet adherence to venules in mice over time. Mice were pretreated (black circles) or not (white
circles) with L-NAME and then transfused with calcein-AM labeled platelets as above. Intravital microscopy was used to visualize fluorescent
platelets transiently adhering to mesenteric venules 0–20 min after superfusion with 10 l of 1 mM histamine. Quantitative analysis of platelet
adhesion as a function of time after the secretagogue application is shown (n  4–5 mice  SEM, *p  0.05 and **p  0.01 versus nontreated).
does not affect NSF ATPase activity, NO may uncouple Importance of Cysteine Residues to NSF Function
Our data emphasize the importance of cysteine residuesthe ability of NSF to convert the chemical energy of
ATP hydrolysis into the mechanical energy necessary to the function of NSF. Specific cysteine residues play
a role in ATP hydrolysis: mutation of C21, C91, C264,to separate the SNARE complex. NSF C91 is not adja-
cent to the N-terminal-D1 region linker, where its modifi- and C334 reduces the ATPase activity of NSF by approx-
imately 50% (Figure 4B). C264 is located within thecation might influence a conformational change of NSF.
However, NSF C264 is located within the D1 domain Walker A motif of the D1 domain, and C334 is located
three residues away from the Walker B motif of the D1Walker A motif, which interacts with ATP, and it is possi-
ble that nitrosylation of C264 may affect the efficiency domain, so mutation of these residues may alter ATP
binding or hydrolysis. Specific cysteine residues C11,by which ATP hydrolysis is converted into mechanical
energy. C21, C334, C568, and C582 are necessary for NSF to
Cell
148
erous gifts from James E. Rothman (Rockefeller University, NY).interact with the SNARE complex. Mutation of C11 and
Mice were purchased from Jackson Laboratories (Bar Harbor, ME).C21 in the N-terminal domain may interfere with the
ability of NSF to interact with -SNAP. Mutation of the
Peptides
cysteine residues C334 in the D1 domain and C568 and Peptides were synthesized by Anaspec, Inc. (San Jose, CA). The
C582 in the D2 domain may affect the structure of NSF TAT-NSF222 fusion polypeptide sequence is: YGRKKRRQRRRGG-
necessary for interaction with SNARE molecules. Finally, GLDKEFNSIFRRAFASRVFPPE. The control peptide TAT-NSF222scr
sequence is: YGRKKRRQRRRGG-GENSFRFLADIFPAKAFPVRFE.cysteine residues C91 and C264 are necessary for NSF
to disassemble the SNARE complex.
Preparation of Recombinant NSF and SNARE Polypeptides
Recombinant RGS-(His)6-NSF and RGS-(His)6--SNAP were ex-
How Does NO Inhibition of NSF Inhibit Exocytosis? pressed in bacteria and purified on a Ni-NTA-agarose column (His-
TRAP, Amersham, Uppsala, Sweden). Recombinant GST-SNARENO inhibition of NSF is a mechanism by which NO can
proteins were expressed in BL21 cells and purified with glutathione-regulate exocytosis. NSF is required for vesicle traffick-
agarose (GSTrap, Amersham). For some assays, the GST tag wasing, although the precise stage at which it acts is unclear.
cleaved off of the GST-SNARE polypeptide with thrombin.
NSF was originally thought to prime vesicles for fusion
with target membranes. NSF activity is required prior Cell Culture and Analysis of vWF Release
to exocytosis in Drosophila (Littleton and Bellen, 1995; Human aortic endothelial cells (HAEC) and EGM-2 media were ob-
tained from Clonetics (Walkersville, MD). HAEC were pretreated withLittleton et al., 1998). The NSF homolog Sec18 is neces-
NO donors, washed, stimulated with 1 U/ml of thrombin, and thesary prior to vacuole fusion in yeast (Mayer and Wickner,
amount of vWF released into the media was measured by an ELISA1997; Mayer et al., 1996; Nichols et al., 1997). Finally,
(American Diagnostica, Greenwich, CT). HAEC were permeabilizedNSF and ATP are necessary for the incorporation of the
by incubation with 10 U/well of SLO (Sigma) in PBS pH 7.4 for 15
rab effector EEA1 into the SNARE complex, which may min at 37	C (Walev et al., 2001). Some cells were incubated with
mediate vesicle tethering prior to fusion (McBride et al., 20–200 g/ml of antibodies or with 100 g/ml of recombinant NSF.
Cells were then resealed by incubation with EGM-2 media for 4 hr1999). However, more recent data suggests that NSF
at 37	C, washed with EGM-2 media, and stimulated with thrombinregulates vesicle trafficking after fusion, disassembling
as above.the SNARE complex to permit recycling of individual
SNARE molecules (Burgoyne and Morgan, 1998). It is
ATPase Assay
also possible that NSF may play distinct roles in different The ATPase activity of NSF was measured by a coupled assay in
organisms or that NSF may regulate multiple stages of which ATP utilization is linked to the pyruvate kinase reaction, which
vesicle transport. Whether NSF regulates vesicle traf- generates pyruvate, which in turn is measured continuously with
lactate dehydrogenase (Huang and Hackney, 1994). Recombinantficking prior to or following membrane fusion, NSF is
NSF (0.2 g/l) was pretreated with buffer or DEA or DEA-NONOatenecessary for membrane fusion, and NO inhibition of
or NEM for 10 min at 22	C. ATPase reaction buffer (100 mM HEPESNSF is a mechanism by which NO can regulate exo-
buffer [pH 7.0], 100 mM KCl, 10 mM MgCl2, 5 mM CaCl2, 10 mMcytosis. ATP, 5 mM phosphoenol pyruvate, 50 U lactate dehydrogenase,
and 50 U pyruvate kinase) was added to the mixture, followed by
10l of NADH (2 mg/ml in 1% sodium bicarbonate). The mixture wasImplications for Regulation of Exocytosis
incubated for 10 min at 22	C, and the absorbance was measured at
NO inhibition of NSF is one possible mechanism for the 340 nm.
anti-inflammatory effects of NO. NO derived from NOS3
in endothelial cells or NOS2 in macrophages can nitrosy- NSF Disassembly Assay
late and inhibit NSF, decreasing Weibel-Palade body Analysis of the 7S and 20S complexes was performed according to
previously published protocols (Sollner et al., 1993). The disassem-exocytosis, and limiting leukocyte rolling and activation.
bly activity of NSF was measured by a coprecipitation assay (Pev-Conversely, lack of NO and increased Weibel-Palade
sner et al., 1994). Recombinant RGS-(His)6-NSF (0.1 g/l) was pre-body exocytosis may explain in part the increased risk
treated with buffer or 1.0 mM DEA or DEA-NONOate for 10 min
for vascular inflammation and atherosclerosis in pa- at 22	C. Recombinant RGS-(His)6--SNAP (0.1 g/l), and SNARE
tients with impaired vascular NO synthesis. Finally, our polypeptides (0.1 g/l each of VAMP-3, SNAP-23, and GST-Syn-
observations may have significance for other areas taxin-4) were added, followed by either 5 mM ATP/10 mM MgCl2
or 5 mM ATP-S/10 mM MgCl2. This mixture of NSF and SNAREof biology as well. NO nitrosylation of NSF may be a
polypeptides was then incubated in binding buffer (4 mM HEPESmechanism for regulation of a variety of physiological
pH 7.4, 0.1M NaCl, 1 mM EDTA, 3.5 mM CaCl2, 3.5mM MgCl2, andprocesses mediated by granule exocytosis, including
0.5% Nonidet P-40) and glutathione-sepharose beads for 1 hr at
neurotransmission, platelet thrombosis, and cytotoxic 4	C with rotation. The beads were washed with binding buffer 4
T lymphocyte killing. times, mixed with SDS-PAGE sample buffer, boiled for 3 min, and
analyzed by immunoblotting.
Experimental Procedures
Determination of S-Nitrosylation of NSF
Measurement of cysteine residues nitrosylated in vitro was per-Materials
formed by the Saville and Griess assays (Saura et al., 1999). Mea-Thrombin was purchased from Enzyme Research Laboratories
surement of NSF nitrosylated in cultured cells was performed by(South Bend, IN). Diethylamine (DEA)-NONOate and dithylenetria-
immunoprecipitation with antibody to nitrosocysteine, followed bymine (DETA)-NONOate were purchased from Cayman Chemical
immunoblotting with antibody to NSF. Measurement of cysteine(Ann Arbor, MI). Calcein-acetoxymethylester was purchased from
residues nitrosylated in vivo was performed as previously (JaffreyMolecular Probes (Eugene, OR). Mouse monoclonal antibody to
et al., 2001; Jaffrey and Snyder, 2001).syntaxin-4 was from BD Biosciences (Bedford, MA). Rabbit poly-
clonal antibodies to NSF (H-300), -SNAP (FL-295), and VAMP (FL-
118) were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Bleeding Times in Mice
Measurement of bleeding time in mice was performed as previouslyThe antibody to nitrosocysteine was from Calbiochem (San Diego,
CA). The cDNAs of RGS-His6-NSF and RGS-His6--SNAP were gen- described (Weiss et al., 2002). Mice were anesthetized with an intra-
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muscular injection of ketamine and xylazine, and 5 mm of the distal Snyder, S.H. (2001). Protein S-nitrosylation: a physiological signal
for neuronal nitric oxide. Nat. Cell Biol. 3, 193–197.tip of the tail was amputated. The tail was blotted with filter paper
every 5 s until the paper was no longer stained. If the animals bled Jahn, R., and Sudhof, T.C. (1999). Membrane fusion and exocytosis.
for 20 min, the experiment was stopped, and the bleeding time was Annu. Rev. Biochem. 68, 863–911.
recorded as 20 min. Jahn, R., Lang, T., and Sudhof, T.C. (2003). Membrane fusion. Cell
112, 519–533.
Platelet Adherence to Venules in Mice Kaiser, C.A., and Schekman, R. (1990). Distinct sets of SEC genes
Measurements of platelet adherence in mice was adapted from govern transport vesicle formation and fusion early in the secretory
Andre et al. (2000). Mice were injected or not with 5 mg/kg L-NAME pathway. Cell 61, 723–733.
intravenously, and after 30 min, transfused with calcein-acetoxy-
Kuhlencordt, P.J., Chen, J., Han, F., Astern, J., and Huang, P.L.methylester (calcein-AM)-labeled murine platelets (Denis et al.,
(2001a). Genetic deficiency of inducible nitric oxide synthase re-1998). The animals were then prepared for intravital microscopy
duces atherosclerosis and lowers plasma lipid peroxides in apolipo-with an externalized mesentery (Ni et al., 2000). One mesenteric
protein E-knockout mice. Circulation 103, 3099–3104.venule (130–180 m in diameter) per animal was filmed for 2 min
Kuhlencordt, P.J., Gyurko, R., Han, F., Scherrer-Crosbie, M., Aretz,before and 20 min after a topical superfusion of 10 l of 1 mM
T.H., Hajjar, R., Picard, M.H., and Huang, P.L. (2001b). Acceleratedhistamine. Platelet adherence was expressed as the number of ad-
atherosclerosis, aortic aneurysm formation, and ischemic heart dis-hering fluorescent cells per square millimeter of venular surface,
ease in apolipoprotein E/endothelial nitric oxide synthase double-calculated from the diameter and length of segment viewed.
knockout mice. Circulation 104, 448–454.
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